20-Hydroxyeicosatetraeonic Acid: A New Target for the Treatment of Hypertension
- 1 October 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Pharmacology
- Vol. 56 (4), 336-344
- https://doi.org/10.1097/fjc.0b013e3181f04b1c
Abstract
Arachidonic acid is metabolized by enzymes of the CYP4A and 4F families to 20-hydroxyeicosatetraeonic acid (20-HETE), which plays an important role in the regulation of renal function, vascular tone, and the long-term control of arterial pressure. In the vasculature, 20-HETE is a potent vasoconstrictor, and upregulation of the production of this compound contributes to the elevation in oxidative stress and endothelial dysfunction and the increase in peripheral vascular resistance associated with some forms of hypertension. In kidney, 20-HETE inhibits Na+ transport in the proximal tubule and thick ascending loop of Henle, and deficiencies in the renal formation of 20-HETE contributes to sodium retention and development of some salt-sensitive forms of hypertension. 20-HETE also has renoprotective actions and opposes the effects of transforming growth factor β to promote proteinuria and renal end organ damage in hypertension. Several new inhibitors of the synthesis of 20-HETE and 20-HETE agonists and antagonists have recently been developed. These compounds along with peroxisome proliferator-activated receptor-α agonists that induce the renal formation of 20-HETE seem to have promise as antihypertensive agents. This review summarizes the rationale for the development of drugs that target the 20-HETE pathway for the treatment of hypertension and associated cardiovascular complications.Keywords
This publication has 164 references indexed in Scilit:
- 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid Mediates Endothelial Dysfunction via IκB Kinase-Dependent Endothelial Nitric-Oxide Synthase UncouplingThe Journal of pharmacology and experimental therapeutics, 2009
- Increased Renal Proximal Convoluted Tubule Transport Contributes to Hypertension in Cyp4a14 Knockout MiceNephron Physiology, 2009
- Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injuryKidney International, 2009
- Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injuryAutonomic & Autacoid Pharmacology, 2009
- Effect of 20-HETE Inhibition on Infarct Volume and Cerebral Blood Flow after Transient Middle Cerebral Artery OcclusionJournal of Cerebral Blood Flow & Metabolism, 2008
- Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injuryAmerican Journal of Physiology-Renal Physiology, 2008
- Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- A 20-HYDROXYEICOSATETRAENOIC ACID AGONIST, N-[20-HYDROXYEICOSA-5(Z),14(Z)-DIENOYL]GLYCINE, OPPOSES THE FALL IN BLOOD PRESSURE AND VASCULAR REACTIVITY IN ENDOTOXIN-TREATED RATSShock, 2008
- Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrierAmerican Journal of Physiology-Renal Physiology, 2007
- Fenofibrate lowers blood pressure in two genetic models of hypertensionCanadian Journal of Physiology and Pharmacology, 2000